Estrogens and aspects of prostate disease

International Journal of Urology

Volumn 14, Issue 1, 2007, Pages 1-16

  Prezioso, Domenico ^a   Denis, Louis J ^a   Klocker, Helmut ^a   Sciarra, Alexandria ^a   Reis, Mario ^a   Naber, Kurt ^a   Lobel, Bernard ^a   Pacik, Dalibor ^a   Griffiths, Keith ^a  

^a Oncology Centre of Antwerp   (Belgium)

Author keywords

Chemoprevention; Estrogens; Phyto estrogens; Prostate

Indexed keywords

ANDROSTENEDIONE; ANTIESTROGEN; AROMATASE INHIBITOR; ATAMESTANE; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GONADOTROPIN; GROWTH HORMONE; INSULIN; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MEPARTRICIN; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN; TAMOXIFEN; TESTOSTERONE; TZA 2237;

ACROMEGALY; ADOLESCENCE; BRAIN; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME 1; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CORONAVIRUS; DISEASE ASSOCIATION; DNA DAMAGE; DNA SEQUENCE; DOG; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TOLERABILITY; ENDOCRINE DISEASE; ETHNIC DIFFERENCE; FAT INTAKE; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; GENETIC POLYMORPHISM; GENOME IMPRINTING; HORMONAL THERAPY; HORMONE RELEASE; HUMAN; HYPERINSULINEMIA; HYPOTHALAMUS; INSULIN RESISTANCE; MISSENSE MUTATION; MULTIGENE FAMILY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PELVIS PAIN SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; PUBERTY; RAT STRAIN; REVIEW; SEXUALITY; TESTOSTERONE BLOOD LEVEL; TRANSGENIC MOUSE; X CHROMOSOME;

ESTROGENS; HUMANS; MALE; PRACTICE GUIDELINES; PROSTATIC DISEASES; PROSTATIC NEOPLASMS; PROSTATITIS;

EID: 33845672712     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01476.x     Document Type: Review

References (141)

1. Burrows H. The localisation of response to oestrogenic compounds in the organs of male mice. J. Pathol. 1935; 51: 423-9.
2. De Jongh SE. Der Einflass von Geschlechtshormonen auf die Prostata und ihr Umgebung bei der Maus. Acta Brev. Neeri Physiol. Pharmacol. Microbiol. 1935; 5: 28-32.
3. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer 2: the effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 1941; 43: 209-23.
4. Holtgrewe HL, Ackermann R, Bay-Nielsen H et al. The economics of BPH. In: Cockett ATK, Khoury S, Aso Y et al. (eds). The Third International Consultation on Benign Prostatic Hyperplasia (BPH). SCI, Paris, 1996; 53-70.
5. Bartsch G, Klocker H, Ackermann R et al. Translational research areas and new treatment modalities. In: Murphy G, Khoury S, Partin A, Denis L. (eds). Second International Consultation on Prostate Cancer. Health Publication Ltd, Plymouth, 2000; 59-136.
6. Griffiths K, Denis LJ, Turkes A. Oestrogens, Phyto-Oestrogens and the Pathogenesis of Prostatic Disease. Martin Dunitz, London, 2002.
7. Denis LJ, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993; 72: 3888-95.
8. Denis LJ. Prostate cancer: a continuum of controversy. Eur. J. Cancer 1995; 31A: 839-40.
9. Denis LJ, Murphy GP, Schroeder FH. Report of the consensus workshop on screening and global strategy for prostate cancer. Cancer 1995; 75: 1187-207.
10. Chaisari N, Pierrepoint CG. Examination of the distribution of oestrogen receptor between the stromal and epithelial compartments of the canine prostate. Prostate 1980; 1: 357-66.
11. Coffey DS, Walsh PC. Clinical experimental studies of benign prostatic hyperplasia. Urol. Clin. North Am. 1990; 17: 461-75.
12. Nicholson RI, Davies P, Griffiths K. Interaction of androgens with oestradiol-17β receptor proteins in DMBA-induced mammary tumours: a possible oncolytic mechanism. Eur. J. Cancer 1978; 14: 439-45.
13. Coffey DS. Similarities of prostate and breast cancer: evolution, diet and estrogens. Urology 2001; 57 (Suppl.): 31-8.
14. Bektic J, Wrulich OA, Dobler G et al. Identification of genes involved in estrogenic action in the human prostate using microarray analysis. Genomics 2004; 83: 34-44.
15. Huggins C. Introduction. In: Vollmer EP, Kauffmann G (eds). Biology of the Prostate and Related Tissues. Monogr. 12, Natl Cancer Inst. US Department Health, Education & Welfare, Bethesda, 1963; xi-xii.
16. Rotkin ID. Epidemiologic clues to increased risk of prostae cancer. In: Spring-Mills E, Hafez ESE (eds). Male Accessory Sex Glands: Biology and Pathology. Elsevier/North-Holland Medical Press, Amsterdam, 1980; 289-311.
17. Griffiths K and the Internatonal Prostate Health Council Study Group. Estrogens and prostatic disease, (Review). Prostate 2000; 45: 87-100.
18. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad. Sci. USA 1992; 89: 3367-71.
19. Gonzalgo ML, Isaacs WB. Molecular pathways to prostate cancer. J. Urol. 2003; 170: 2444-52.
20. Giovannucci E, Stampfer MJ, Krithivas K et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl Acad. Sci. USA 1997; 94: 3320-3.
21. Makridakis N, Poss RK, Pike MC et al. A prevalent mis-sense substitution that modulates activity of prostatic steroid 5alpha reductase. Cancer Res. 1997; 57: 1020-2.
22. Reichardt JKV, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 1995; 55: 3973-5.
23. Weihua Z, Makela S, Andersson LC et al. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc. Natl Acad. Sci. USA 2001; 98: 6330-5.
24. Makridakis NM, Ross RK, Pike MC et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles. Lancet 1999; 354: 975-8.
25. Culig Z, Klocker H, Bartsch G, Hobisch A. Androgen receptors in prostate cancer. Endocr Relat Cancer 2002; 9: 155-70.
26. Matthews J, Gustafsson J-A. Estrogen signaling: a subtle balance between ER alpha and ER beta (Review). Mol. Interv. 2003; 3: 281-92.
27. Herbst AL, Ulfeloer H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilboestrol therapy with tumor appearance in young women. N. Engl. J. Med. 1971; 284: 878-81.
28. Trichopoulos D. Hypothesis: does breast cancer originate in utero? Lancet 1990; 21: 939-40.
29. Newbold RR, McLachlan JA. Diethylstilboestrol-associated defects in murine genital tract development. In: McLauchlan JA (ed.). Estrogens in the Environment: Influences on Development. Elsevier, North-Holland, New York, 1985; 288-318.
30. Naslund M, Coffey D. The differential effects of neonatal androgen, estrogen and progesterone on adult rat prostate growth. J. Urol. 1986; 136: 1136-40.
31. Chang WY, Birch L, Woodham C, Gold LI, Prins GS. Neonatal estrogen exposure alters the transforming growth factor-beta signaling system in the developing rat prostate and blocks the transient p21 (cip1/waf1) expression associated with epithelial differentiation. Endocrinology 1999; 140: 2801-13.
32. Levine S. Sexual differentiation: the development of maleness and femaleness. Calif. Med. 1971; 114: 12-17.
33. Vom Saal FS, Timms BG, Montano MM et al. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc. Natl Acad. Sci. USA 1997; 94: 2056-61.
34. Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HI. The early in utero oestrogen and testosterone environment of black and whites: potential effects on male offspring. Br. J. Cancer 1988; 57: 216-18.
35. Solter D. Differential imprinting and expression of maternal and paternal genomes. Annu. Rev. Genet. 1988; 22: 127-46.
36. DeChiara TM, Robertson EJ, Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991; 64: 849-59.
37. Jaenisch R, Beard C, Li E. DNA methylation and mammalian development. In: Ohlsson R, Hall K, Ritzen M (eds). Genomic Imprinting: Causes and Consequences. Cambridge University Press, Cambridge, 1995; 118-26.
38. Wilkins RJ. Genomic imprinting and carcinogenesis. Lancet 1988; 1: 329-31.
39. Adams JB. Control of secretion and the function of C19-delta5-steroids of the human adrenal gland. Mol. Cell. Endocr. 1985; 41: 1-17.
40. Syms AJ, Harper ME, Griffiths K. The effect of prolactin on human BPH epithelial cell proliferation. Prostate 1985; 6: 145-53.
41. Dillner K, Kindblom J, Flores-Morles A et al. Molecular characterization of prostate hyperplasia in polactin-transgenic mice by using cDNA representational difference analysis. Prostate 2002; 52: 139-49.
42. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors and IGF binding proteins in primary cultures of prostate epithelial cells. J. Clin. Endocrinol. Metab. 1991; 73: 401-7.
43. Grant ES, Ross MB, Ballard S, Naylor A, Habib F. The insulin-like growth factor type I receptor stimulates growth and suppresses apoptosis in prostate stromal cells. J. Clin. Endocrinol. Metab. 1998; 83: 3252-7.
44. Torring N, Vinter-Jensen L, Pedersen SB, Sorensen FB, Flyvbjerg A, Nexo E. Systemic administration of insulin-like growth factor (IGF-I) causes growth of the rat prostate. J. Urol. 1998; 158: 222-7.
45. Anders J, Bang P, Hertel NT et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents and adults: relation to age, sex, stage of puberty, testicular size and body mass index. J. Clin. Endocrinol. Metab. 1994; 78: 744-52.
46. Hiney JK, Srivastava V, Nyberg CL, Ojeda SR, Dess WL. Insulin-like growth factor-I of peripheral origin acts centrally to accelerate the initiation of female puberty. Endocrinology 1996; 137: 3717-28.
47. Baserga R, Perluzzi F, Reiss K. The IGF-I receptor in cancer biology. Int. J. Cancer 2003; 107: 873-7.
48. Ruan W, Powell-Braxton L, Kopchick JJ, Kleinberg DL. Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 1999; 140: 1984-9.
49. Chan JM, Stampfer MJ, Giovannucci E et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-56.
50. Chokkalingam AP, Gao Y-T, Deng J et al. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 2002; 52: 98-105.
51. Turkes A, Peeling WB, Griffiths K. Serum IGF-1 determination in relation to prostate cancer screening: possible differential diagnosis in relation to PSA assays. Prostate Cancer Prostatic Dis. 2000; 3: 173-5.
52. Robinson ICAF, Lightman SL. Differential regulation of the growth hormone receptor gene: effects of dexamethasone and estradiol. Endocrinology 1996; 137: 3891-6.
53. Colao AM, Marzullo O, Spiezia S et al. Effect of growth hormone (GH) and insulin-like growth factor-I on prostatic diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency and healthy subjects. J. Clin. Endocrinol. Metab. 1999; 84: 1986-91.
54. Orme SM, McNally R, Staines A, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J. Clin. Endocrinol. Metab. 1998; 83: 2730-4.
55. Pollak M, Costantino J, Polychronakos C et al. Effect of tamoxifen on serum insulin-like growth factor-I levels in stage 1 breast cancer patients. J. Natl Cancer Inst. 1990; 82: 1693-7.
56. Danutra V, Turkes A, Read GF et al. Progesterone concentrations in samples of saliva from adolescent girls living in Britain and Thailand , two countries where women are at widely differing risk of breast cancer. J. Endocrinol. 1988; 121: 375-81.
57. Wilson DW, Turkes A, Jones R, Danutra V, Read GR, Griffiths K. A comparison of menstrual cycle profiles of salivary progesterone in British and Thai adolescent girls. Eur. J. Cancer 1992; 28A: 1162-7.
58. Cheung CC, Thornton JE, Kuijper JL, Weigle DS, Clifton DK, Steiner RA. Leptin is a metabolic gate for the onset of puberty in the female rat. Endocrinology 1997; 138: 855-8.
59. Bray GA, York DA. Leptin and clinical medicine: a new piece in the puzzle of obesity. J. Clin. Endocrinol. Metab. 1997; 82: 2771-6.
60. Steiner RA. Editorial: Lords and ladies leapin' on leptin. Endocrinology 1996; 137: 4533-4.
61. Kaaks R. Nutrition, hormones and breast cancer: is insulin the missing link? Cancer Causes Control 1996; 7: 605-25.
62. Toscano V, Balducci P, Bianchi P, Mangiantini A, Sciarra F. Steroidal and nonsteroidal factors in plsma sex hormone binding globulin regulation. J. Steroid Biochem. Mol. Biol. 1992; 43: 431-7.
63. Apter D, Vihko R. Endocrine determinants of fertility: serum androgen concentrations during follow-up of adolescents into the third decade of life. J. Clin. Endocrinol. Metab. 1990; 71: 970-4.
64. Griffiths K, Coffey DS, Cockett ATK et al. The regulation of prostatic growth. In: The Third International Consultation on Benign Prostatic Hyperplasia (BPH). Cockett ATK, Khoury S, Aso Y et al. (eds). SCI, Paris, 1996; 73-115.
65. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989; 15 (Suppl. 2): 33-50.
66. McNeal JE. Anatomy of the prostate and morphogenesis of BPH. In: Kimball FA, Buhl AE, Carter DB (eds). New Approaches to the Study of Benign Prostatic Hyperplasia. Alan R. Liss, New York, 1984; 27-53.
67. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int. J. Cancer 2003; 107: 1-10.
68. Bruengger A, Bartsche G, Hollinger BE, Holly B, Rohr HP. Smooth muscle cell of the canine prostate in spontaneous benign hyperplasia, steroid induced hyperplasia and estrogen or tamoxifen treated dogs. J. Urol. 1983; 130: 1208-10.
69. Sakr WA. High-grade prostatic intraepithelial neoplasia: additional links to a potentially more aggressive prostate cancer? J. Natl Cancer Inst. 1998; 90: 486-7.
70. Sakr WA. Prostatic intraepithelial neoplasia: a marker for high-risk groups and a potential target for chemoprevention. Eur. Urol. 1999; 35: 474-8.
71. Harper ME, Goddard L, Glynne-Jones E, Peeling WB, Gffiths K. Epidermal growth factor expression by northern analysis and immunohistochemistry in benign and malignant prostatic tumours. Eur. J. Cancer 1995; 31: 1492-7.
72. Harper ME, Glynne-Jones E, Goddard L, Mathews P, Nicholson RI. Expression of androgen receptor and growth factors in premalignant lesions of the prostate. J. Pathol. 1998; 186: 169-77.
73. Bonaccorsi L, Carloni V, Muratori M et al. EGF receptor (EGFR) signalling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor. Int. J. Cancer 2004; 112: 78-86.
74. Boyle P, Napalkov P, Barry MJ et al. Epidemiology and natural history of prostate cancer. In: Murphy GP, Denis L, Chatelain C, Griffiths K, Khoury S, Cockett ATK (eds). First International Consultation on Prostate Cancer. SCI, Paris, 1997; 1-29.
75. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol. 1993; 150: 379-85.
76. Sakr WA, Grignon DJ, Haas GP. Pathology of premalignant lesions and carcinoma of the prostate in African-American men. Semin. Urol. Oncol. 1998; 16: 214-20.
77. Vermeulen A, Giagulli VA. Andropause. In: Studd J (ed.). The Management of the Menopause. Carnforth Parthenon Publishing, Carnforth, 1998; 279-96.
78. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J. Natl Cancer Inst. 1986; 76: 45-8.
79. Wilson DW, Harper ME, Jensen HM et al. A prognostic index for the clinical management of patients with advanced prostatic cancer: a British Prostate Study Group investigation. Prostate 1985; 7: 131-41.
80. Meikle AW, Smith JR, West DW. Familial factors affecting prostatic cancer risk and plasma sex-steroid levels. Prostate 1985; 6: 121-8.
81. De Marzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003; 361: 955-64.
82. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol. 1999; 155: 1985-92.
83. Steed PM, Tansey MG, Zalevsky J et al. Inactivation of TNF signalling by rationally designed dominant-negative TNF variants. Science 2003; 301: 1895-8.
84. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002; 60: 78-83.
85. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000; 56: 828-32.
86. Prezioso D, Naber KG, Lobel B et al. Some historical perspectives on the pathogenesis of prostatitis. Acad. Med. Sci. In press.
87. Franks LM, McNeal JE. Discussion, Third Tenovus Workshop on 'Some Aspects of the Aetiology and Biochemistry of Prostate Cancer'. Griffiths K, Pierrepoint CG (eds). Alpha Publishing, Cardiff 1970; 39-46.
88. Oberley TD, Zhong W, Szweda LI, Oberley LW. Localization of antioxidant enzymes and oxidative damage products in normal and malignant prostate epithelium. Prostate 2000; 44: 144-55.
89. Zha S, Gage WR, Sauvageot J et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate cancinoma. Cancer Res. 2001; 61: 8617-23.
90. Deutsch E, Maggiorella L, Eschwege P, Bourhis J, Soria JC, Abdulkarim B. Environmental, genetic and molecular features of prostate cancer. Lancet Oncol. 2004; 5: 303-13.
91. Montano MM, Jaiswal AK, Katzenellenbogan BS. Transcriptional regulation of the human quinone reductase gene by anti-estrogen liganded estrogen receptor-alpha and estrogen receptor-beta. J. Biol. Chem. 1998; 273: 25443-9, i.
92. Jeronimo C, Usadel H, Henrique R et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 2001; 93: 1747-52.
93. Maruyama R, Toyooka S, Toyooka KO et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res. 2002; 8: 514-19.
94. Lee WH, Morton RA, Epstein JI et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostaic carcinogenesis. Proc. Natl Acad. Sci. USA 1994; 91: 11 733-7.
95. Kuzmin I, Gillespie JW, Protopopov A et al. The RASSF1A tumour suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res. 2002; 62: 3498-502.
96. Sasaki M, Tanaka Y, Perinchery G et al. Methylation and inactivation of estrogen, progesterone and androgen receptors in prostate cancer. J. Natl Cancer Inst. 2002; 94: 384-90.
97. Pasquali D, Rossi V, Esposito D et al. Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J. Clin. Endocrinol. Metab. 2001; 86: 2051-5.
98. Cunha GR, Donjacour AA, Cooke PS et al. The endocrinology and development biology of the prostate. Endocr. Rev. 1987; 8: 338-62.
99. McKeehan WL, Wang F, Kan M. The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog. Nucleic Acid Res. Mol. Biol. 1998; 59: 135-76.
100. Krieg M, Nass R, Tunn S. Effect of ageing on endogenous level of 5α-dihydrotestosterone, testosterone, estradiol and estrone in epithelium and stroma of normal and hyperplastic human prostate. J. Clin. Endocrinol. Metab. 1993; 77: 375-81.
101. Shibata Y, Ito K, Suzuki K et al. Changes in the endocrine environment of the human prostate transition zone with ageing: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 2000; 42: 45-55.
102. Risbridger G, Wang H, Frydenberg M, Cunha GR. The metplastic effects of estrogen on prostate epithelium proliferation of cells with basal cell phenotype. Endocrinology 2001; 142: 2443-50.
103. Wang YZ, Wong YC. Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 1998; 35: 165-77.
104. Wang YZ, Hayward SW, Cao M, Young P, Cardiff R, Cunha GR. Role of estrogen signalling in prostatic hormonal carcinogenesis. J. Urol. 2001; 165: 1320.
105. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tisty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999; 59: 5002-11.
106. van Kempen LCL, Rhee J-S, Dehne K, Lee J, Edwards DR, Coussens LM. Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. Differentiation 2002; 60: 610-23.
107. Foster BA, Evangelou A, Gingrich JR, Kaplan PJ, DeMayo F, Greenberg NM. Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib provides the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation 2002; 60: 624-32.
108. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA 1996; 93: 5925-30.
109. Kuiper GG, Carlsson B, Grandien K et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138: 863-70.
110. Krege JH, Hodgin JB, Couse JF et al. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc. Natl Acad. Sci. USA 1998; 95: 15 677-82.
111. Paech K, Webb P, Kuiper GGJM et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP-1 sites. Science 1997; 277: 1508-10.
112. Bektic J, Berger AP, Pfeil K, Dobler G, Bartsch G, Klocker H. Androgen receptor regulation by physiological concentrations of the isoflavnoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor β. Eur. Urol. 2004; 45: 245-51.
113. Hedlund TE, Johannes WU, Miller GI. Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate 2003; 54: 68-78.
114. Rohlff C, Blagosklonny MV, Kyle E et al. Prostatic cancer cell growth inhibition by tamoxifen is associated with an inhibition of protein kinase C and induction of p21 (waf/cip1). Prostate 1998; 37: 51-9.
115. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepressorrs. Mol. Endocrinol. 1996; 10: 1167-77.
116. Kalkhoven E, Valentine JE, Heery DM, Parker MG. Isoforms of steroid receptor co-activator I differ in their ability to potentiate transcription by the estrogen receptor. EMBO J. 1998; 17: 232-43.
117. Brzozowski AM, Pike ACW, Dauter Z et al. Molecular basis of agonism in the estrogen receptor. Nature 1997; 389: 753-8.
118. Hihi AK, Wahli W. Structure and function of the estrogen receptor. In: Oettel M, Schillinger M (eds). Handbook of Experimental Pharmacology, Vol. 135/I, Estrogens and Antiestrogens. Springer-Verlag, Berlin, 1999; 111-26.
119. Aronica SM, Katzenellenbogen BS. Stimulation of estrogen mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate and insulin-like growth factor-I. Mol. Endocrinol. 1993; 7: 743-52.
120. Cho H, Katzenellenbogen BS. Synergistic activation of estrogen receptor mediated transcription by estradiol and protein kinase activators. Mol. Endocrinol. 1993; 7: 441-52.
121. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by ECF involves the MAP-kinase pathway and direct phosphorylation. EMBO J. 1996; 15: 2174-83.
122. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a base for the cell- and promoter-specific action of these hormones. Mol. Endocrinol. 1996; 10: 119-31.
123. 70, for the androgen receptor in human prostate cells. Proc. Natl Acad. Sci. USA 1996; 93: 5517-21.
124. Jordan VC. Designer Estrogens. Sci. Am. 1998; 279: 60-7.
125. Goldin BR, Adlercreutz H, Gorbach SL et al. Estrogen excretion patterns and plasma levels in vegetarian and omnivorous women. N. Engl. J. Med. 1982; 307: 1542-7.
126. Hamalainen E, Adlercreutz H, Puska P, Pietinen P. Diet and serum hormones in healthy men. J. Steroid Biochem. 1984; 20: 459-64.
127. Barone D, Peroglio F, Toso E, Bruzzese T. Binding of Mepartricin to sex hormones: a key factor of its activity on benign prostatic hyperplasia. Arzneimittel-Forsch. 2001; 51: 984-90.
128. Re G, Badino R, Odore R et al. Effects of Mepartricin on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentrations in adult rats. Pharmacol. Res. 2001; 44: 141-7.
129. Yoshinaka Y, Kobayashi H, Kirihara J, Sato F, Shakutou S, Yamanaka H. Effects of mepartricin (S-160) on spontaneous canine benign prostate hyperplasia. Eur. Urol. 2000; 37: 428-35.
130. Boenm S, Nirnberger G, Ferrari P. Estrogen suppression as a pharmacotherapeutic strategy in the medical treatment of beingn prostatic hyperplasia: evidence for its efficacy from studies with mepartricin. Wien. Klin. Wochenschr. 1998; 110: 817-23.
131. De Rose AF, Gallo F, Giglio M, Carmignani G. Role of Mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomised prospective placbo-controlled trial. Urology 2004; 63: 13-16.
132. Radlmaier A, Eickenberg HU, Fletcher MS et al. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind , placebo-controlled , randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Prostate 1996; 29: 199-208.
133. Gingell JC, Knonagel H, Kurth KH, Tunn UW. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90.062 Study Group. J. Urol. 1995; 154: 399-401.
134. Ito K, Fukabori Y, Shibata Y et al. Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia. Eur. J. Endocrinol. 2000; 143: 543-54.
135. Schherr DS, Reid Pitts W. The nonsteroidal effects of diethylstilboestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J. Urol. 2003; 170: 1703-8.
136. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr. 1988; 7: 165-70.
137. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral stilboestrol as a second-line hormonal agent in advanced prostate cancer. Urology 1998; 52: 257.
138. Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J. Urol. 1995; 154: 1991-8.
139. Schneider MR, Hartmann RW, Sinowatz F, Amselgruber W. Nonsteroidal antiestrogens and partial estrogens wih prostate tumour inhibiting activity. J. Cancer Res. Clin. Oncol. 1986; 112: 258-65.
140. Kirby R, Robertson C, Turkes A et al. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. Prostate 1999; 40: 105-14.
141. Gustafsson J-A. Estrogen receptor β - getting in on the action. Nat. Med. 1997; 3: 493-4.